189 related articles for article (PubMed ID: 9647614)
1. Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
Brown JM
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):12-4. PubMed ID: 9647614
[TBL] [Abstract][Full Text] [Related]
2. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia.
Denny WA; Wilson WR
Expert Opin Investig Drugs; 2000 Dec; 9(12):2889-901. PubMed ID: 11093359
[TBL] [Abstract][Full Text] [Related]
3. Tirapazamine: from bench to clinical trials.
Marcu L; Olver I
Curr Clin Pharmacol; 2006 Jan; 1(1):71-9. PubMed ID: 18666379
[TBL] [Abstract][Full Text] [Related]
4. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
5. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
Brown JM
Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
[TBL] [Abstract][Full Text] [Related]
6. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer.
Wouters BG; Wang LH; Brown JM
Ann Oncol; 1999; 10 Suppl 5():S29-33. PubMed ID: 10582136
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin.
Kovacs MS; Hocking DJ; Evans JW; Siim BG; Wouters BG; Brown JM
Br J Cancer; 1999 Jun; 80(8):1245-51. PubMed ID: 10376978
[TBL] [Abstract][Full Text] [Related]
8. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.
Brown JM
Mol Med Today; 2000 Apr; 6(4):157-62. PubMed ID: 10740254
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia: targeting the tumour.
Boyle RG; Travers S
Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
[TBL] [Abstract][Full Text] [Related]
10. Tirapazamine: a novel agent targeting hypoxic tumor cells.
Reddy SB; Williamson SK
Expert Opin Investig Drugs; 2009 Jan; 18(1):77-87. PubMed ID: 19053884
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of cisplatin activity by the bioreductive agent tirapazamine.
Siemann DW; Hinchman CA
Radiother Oncol; 1998 May; 47(2):215-20. PubMed ID: 9683372
[TBL] [Abstract][Full Text] [Related]
12. Tirapazamine-cisplatin: the synergy.
Gatzemeier U; Rodriguez G; Treat J; Miller V; von Roemeling R; Viallet J; Rey A
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):15-7. PubMed ID: 9647615
[TBL] [Abstract][Full Text] [Related]
13. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial.
Graham MA; Senan S; Robin H; Eckhardt N; Lendrem D; Hincks J; Greenslade D; Rampling R; Kaye SB; von Roemeling R; Workman P
Cancer Chemother Pharmacol; 1997; 40(1):1-10. PubMed ID: 9137522
[TBL] [Abstract][Full Text] [Related]
15. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice.
Durand RE; Olive PL
Radiat Oncol Investig; 1997; 5(5):213-9. PubMed ID: 9372543
[TBL] [Abstract][Full Text] [Related]
16. Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts.
Huxham LA; Kyle AH; Baker JH; McNicol KL; Minchinton AI
Radiother Oncol; 2006 Feb; 78(2):138-45. PubMed ID: 16455148
[TBL] [Abstract][Full Text] [Related]
17. [In vitro oxygen-dependent survival of 2 human cell lines after radiation combined with tirapazamine (SR-4233) and cisplatin].
Lartigau E; Stern S; Guichard M
Cancer Radiother; 2000; 4(3):217-22. PubMed ID: 10897765
[TBL] [Abstract][Full Text] [Related]
18. Effects of bioreductive agents, tirapazamine and mitomycin C, on quiescent cell populations in solid tumors, evaluated by micronucleus assay.
Masunaga S; Ono K; Hori H; Shibata T; Suzuki M; Kinashi Y; Takagaki M; Akaboshi M
Jpn J Cancer Res; 1997 Sep; 88(9):907-14. PubMed ID: 9369940
[TBL] [Abstract][Full Text] [Related]
19. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
Siim BG; van Zijl PL; Brown JM
Br J Cancer; 1996 Apr; 73(8):952-60. PubMed ID: 8611431
[TBL] [Abstract][Full Text] [Related]
20. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.
Olive PL
Br J Cancer; 1995 Mar; 71(3):529-36. PubMed ID: 7880735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]